Atrasentan
(MOTJMGVDPWRKOC-QPVYNBJUSA-N)
Structure
- SMILES
- CCCCN(C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(cc1)OC)C(=O)O)c1ccc2c(c1)OCO2)CCCC
- Type(s)
- Investigational
- Molecular Formula:
- C29H38N2O6
- Molecular Weight:
- 510.622
- Log P:
- 4.6319
- Hydrogen Bond Acceptor:
- 8
- Hydrogen Bond Donor:
- 1
- TPSA:
- 88.54
- CAS Number(s):
- 173937-91-2
Synonym(s)
1.
Atrasentan
2.
(11C)ABT-627
3.
2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid
4.
A 127722
5.
A 147627
6.
A-127722
7.
A-127722.5
8.
A-147627
9.
ABT 627
10.
ABT-627
11.
Atrasentan Hydrochloride
12.
Xinlay
13.
A 127722.5
14.
A127722
15.
A127722.5
16.
A147627
17.
ABT627
External Link(s)
| MeSH | D000077868 |
| PubChem Compound | 159594 |
| BindingDB | 50051007 |
| ChEBI | 135810 |
| CHEMBL | CHEMBL9194 |
| DrugBank | DB06199 |
| IUPHAR/BPS Guide to PHARMACOLOGY | 3487 |
| Therapeutic Target Database | D0Y6UU |
| ZINC | 3812144 |
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Cardiovascular Diseases | 16219361 | CTD | |
| 2 | Hypotension | 10877991 | CTD | |
| 3 | Lung Neoplasms | 17032313 | CTD | |
| 4 | Nasopharyngeal Neoplasms | 17032313 | CTD | |
| 5 | Neoplasms | 16219361 | CTD | |
| 6 | Prostatic Neoplasms | 21275367 | CTD | |
| 7 | Renal Insufficiency | 19326569 | CTD | |
| 8 | Urinary Retention | 15371886 | CTD |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120262
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.